<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00683436</url>
  </required_header>
  <id_info>
    <org_study_id>NG2-73-205</org_study_id>
    <nct_id>NCT00683436</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs</brief_title>
  <official_title>A Multi-Center, Randomized, Blinded, Active and Placebo-Controlled, Crossover Study of the Efficacy and Safety of Two Doses of Adipiplon Bilayer Tablets in Primary Insomniacs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurogen Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurogen Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a multi-center, randomized, blinded, comparative, placebo-controlled, 4 arm&#xD;
      crossover study in patients with primary insomnia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective patients will spend 2 nights in the sleep lab for baseline PSG assessments. Those&#xD;
      who meet the protocol inclusion/exclusion criteria will return for four treatment periods&#xD;
      with two consecutive nights in each. Study medication will be administered in the sleep&#xD;
      laboratory 30 minutes before the patient's usual bedtime.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">November 2008</completion_date>
  <primary_completion_date type="Anticipated">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The study will involve PSG measurement of sleep onset and maintenance.</measure>
    <time_frame>two consecutive nights on each treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The study will involve subjective measures of sleep and next day function.</measure>
    <time_frame>two consecutive nights on each treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Primary Insomnia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adipiplon 6 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adipiplon 9 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ambien CR 12.5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adipiplon</intervention_name>
    <description>bilayer tablets 6 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ambien CR</intervention_name>
    <description>Ambien CR 12.5 mg</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adipiplon</intervention_name>
    <description>bilayer tablets 9 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be between the ages of 21 and 64 years, inclusive;&#xD;
&#xD;
          -  Have a body mass index (BMI) between 21 and 34 kg/m2, inclusive;&#xD;
&#xD;
          -  Be a primary insomniac as defined by DSM-IV criteria; in particular difficulty with&#xD;
             both sleep initiation and sleep maintenance;&#xD;
&#xD;
          -  Have subjective Latency to Sleep Onset &gt; 45 minutes;&#xD;
&#xD;
          -  Have a mean habitual subjective TST of &lt;6.5 hours;&#xD;
&#xD;
          -  Have a TST of 240 - 420 minutes at each of two baseline PSGs;&#xD;
&#xD;
          -  Have a mean LPS &gt; 20min, with neither value &lt;15 minutes and mean WASO &gt; 40 minutes on&#xD;
             baseline PSGs;&#xD;
&#xD;
          -  Be in good general health as determined by a thorough medical history and physical&#xD;
             examination (including vital signs), 12-lead ECG and clinical laboratory tests;&#xD;
&#xD;
          -  Have clinical laboratory values within normal reference range or not clinically&#xD;
             significantly abnormal as judged by the Principal Investigator;&#xD;
&#xD;
          -  Be off any investigational drug for at least 30 days prior to screening;&#xD;
&#xD;
          -  If the patient is a female of childbearing potential, she must be using an acceptable&#xD;
             method of contraception, must have a negative serum pregnancy test at screening, and&#xD;
             must have a negative urine pregnancy test before randomization.&#xD;
&#xD;
          -  Female patients who have been surgically sterilized or have had a hysterectomy are&#xD;
             eligible if they have a negative pregnancy test at screening;&#xD;
&#xD;
          -  Be able to read, understand, and provide written/dated informed consent before&#xD;
             enrolling in the study, and must be willing to comply with all study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant unstable medical illness;&#xD;
&#xD;
          -  Evidence or history of clinically significant allergic (except for untreated,&#xD;
             asymptomatic, seasonal allergies at time of dosing), hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological&#xD;
             disease;&#xD;
&#xD;
          -  History of cancer other than basal cell carcinoma, squamous cell carcinoma of the skin&#xD;
             or cancer in situ within 5 years of screening;&#xD;
&#xD;
          -  Supine or sitting blood pressure &gt; 140/90 mmHg at the screening or baseline visits;&#xD;
&#xD;
          -  Heart rate &gt;100 bpm at the screening or baseline visits;&#xD;
&#xD;
          -  Within the past three years, clinically significant psychiatric illness, including&#xD;
             chronic psychiatric illness or any Axis I condition;&#xD;
&#xD;
          -  History or presence of chronic pain;&#xD;
&#xD;
          -  History of epilepsy or serious head injury;&#xD;
&#xD;
          -  Other than primary insomnia, a history of clinically significant sleep disorder&#xD;
             including narcolepsy, parasomnia as an adult, circadian rhythm disorder, restless leg&#xD;
             syndrome, or on the initial baseline PSG, sleep apnea [Apnea Hypopnea Index (AHI) &gt;10]&#xD;
             or Periodic Limb Movement Disorder [Periodic Limb Movement Arousal Index (PLMAI) &gt;&#xD;
             10];&#xD;
&#xD;
          -  Any condition that may affect drug absorption;&#xD;
&#xD;
          -  Smokers who habitually smoke more than 10 cigarettes per day or smoke during the&#xD;
             overnight hours;&#xD;
&#xD;
          -  Travel across more than three time zones, an expected change in sleep schedules of 3&#xD;
             hours or more, or involvement in rotating shift work within 14 days prior to screening&#xD;
             or during the study period;&#xD;
&#xD;
          -  Self-report of napping ≥30 minutes more than 2 times per week within the last month;&#xD;
&#xD;
          -  Any clinically significant abnormal finding on physical examination, vital signs, ECG,&#xD;
             or clinical laboratory tests, as determined by the investigator. (The QTc interval&#xD;
             must be ≤430 msec. for males and ≤450 msec for females);&#xD;
&#xD;
          -  Known or suspected diagnosis of Acquired Immune Deficiency Syndrome, or previous or&#xD;
             current positive result on human immunodeficiency virus antibody or antigen testing;&#xD;
&#xD;
          -  History or laboratory finding of positive hepatitis B surface antigen or hepatitis C&#xD;
             core antibody;&#xD;
&#xD;
          -  History of allergies, or known sensitivity, hypersensitivity, or adverse reaction to&#xD;
             any drug similar to adipiplon, including benzodiazepines, or zolpidem, zaleplon,&#xD;
             zopiclone, or eszopiclone;&#xD;
&#xD;
          -  Use of any psychotropic medications, including over-the-counter (OTC) and herbal&#xD;
             products, that may affect sleep/wake function within one week or five half-lives&#xD;
             (whichever is longer) prior to screening or need to use any of these medications at&#xD;
             any time during the study;&#xD;
&#xD;
          -  Pregnant or lactating females;&#xD;
&#xD;
          -  Positive serum pregnancy test at screening or urine pregnancy test at baseline;&#xD;
&#xD;
          -  Recent history (≤ one year) of alcohol or drug abuse, or current evidence of substance&#xD;
             dependence or abuse as defined by DSM-IV criteria;&#xD;
&#xD;
          -  Regular consumption of large amounts of xanthine-containing substances (i.e. more than&#xD;
             5 cups of coffee or equivalent amounts of xanthine-containing substances per day);&#xD;
&#xD;
          -  Have eaten grapefruit or had grapefruit juice from baseline through the completion of&#xD;
             study dosing;&#xD;
&#xD;
          -  Self report of a usual consumption of more than 14 units of alcohol per week;&#xD;
&#xD;
          -  Requiring the concomitant usage of any 3A4 inhibitors;&#xD;
&#xD;
          -  Any prior exposure to adipiplon (formerly known as NG2-73).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Broward Research Group</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurotrials Research, Inc</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep and Behavior Medicine Institute</name>
      <address>
        <city>Vernon Hills</city>
        <state>Illinois</state>
        <zip>60061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince &amp; Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital Sleep Medicine and Research Center</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinilabs, Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-State Sleep Disorders Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>May 21, 2008</study_first_submitted>
  <study_first_submitted_qc>May 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2008</study_first_posted>
  <last_update_submitted>July 21, 2008</last_update_submitted>
  <last_update_submitted_qc>July 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Study Manager</name_title>
    <organization>Neurogen Corporation</organization>
  </responsible_party>
  <keyword>insomnia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adipiplon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

